- Conditions
- Multiple Myeloma, Osteoporosis
- Interventions
- Romosozumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Condition Directory
Multiple Myeloma clinical trials
Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 17, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
471
Shown on this page
12
Current sort
Recently updated
Condition scope
Multiple Myeloma
Additional filters apply within this condition.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
How Multiple Myeloma studies are organized in the registry
Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 421–432 of 471 matching trials for Multiple Myeloma.
Indexed local directory records.
Stored official records
Open in full search- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Cevostamab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Discontinue maintenance therapy SOC
- Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Amyloidosis, Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 5,000 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Myeloma, Multiple Myeloma With Failed Remission, Multiple Myeloma in Relapse, Multiple Myeloma of Bone
- Interventions
- MK-4002
- Drug
- Lead sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more
- Conditions
- Multiple Myeloma, Plasmacytoma, Plasmacytoma of Bone
- Interventions
- CC-486, Lenalidomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Anaheim, California + 49 more
- Conditions
- Multiple Myeloma
- Interventions
- biologic sample preservation procedure, clonality analysis, fluorescence spectroscopy, laboratory biomarker analysis, polymerase chain reaction, protein analysis, quality-of-life assessment
- Other · Genetic · Procedure
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2040
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hodgkin Lymphoma, Multiple Myeloma, Non-hodgkin Lymphoma
- Interventions
- Gcsf, Plerixafor
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Bortezomib, Dexamethasone, Lenalidomide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Charlotte, North Carolina • Madison, Wisconsin
- Conditions
- Amyloidosis, Castleman's Disease, Cryoglobulinemia, Heavy Chain Deposition Disease, Light Chain Deposition Disease, Multiple Myeloma, Plasma Cell Leukemia, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
- Interventions
- Bone Marrow Aspirate and Biopsy
- Procedure
- Lead sponsor
- Michael Tomasson
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
About this Multiple Myeloma clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Multiple Myeloma.